Trinity J Bivalacqua
Overview
Explore the profile of Trinity J Bivalacqua including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
388
Citations
6596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michel K, Slinger M, Stambakio H, Talwar R, Luckenbough A, Kates M, et al.
Eur Urol Focus
. 2024 Oct;
PMID: 39443196
CARE is a pragmatic randomized clinical trial designed to compare adherence, satisfaction, patient out-of-pocket costs, and venous thromboembolism (VTE) rates between apixaban and enoxaparin prescribed as VTE prophylaxis on discharge...
2.
Xia L, Knudsen J, Roberson D, Wood E, Dadabhoy A, Romano S, et al.
BJU Int
. 2024 Oct;
135(1):59-62.
PMID: 39353865
No abstract available.
3.
Downs T, Bailey H, Lozar T, Schmitz N, Green H, Scarlett C, et al.
Cancer Prev Res (Phila)
. 2024 Aug;
18(1):31-39.
PMID: 39187984
We performed a clinical trial in patients with non-muscle-invasive (NMI) urothelial cancer randomized (2:1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally once weekly × 3 doses...
4.
Johnson Iii B, Teply B, Kagemann C, McGuire B, Lombardo K, Jing Y, et al.
Bladder Cancer
. 2024 Aug;
10(2):133-143.
PMID: 39131872
Background: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. Objective: We evaluated the clinical activity and safety of...
5.
Li R, Shah P, Stewart T, Nam J, Bivalacqua T, Lamm D, et al.
Nat Med
. 2024 Jul;
30(8):2377.
PMID: 38956199
No abstract available.
6.
Li R, Shah P, Stewart T, Nam J, Bivalacqua T, Lamm D, et al.
Nat Med
. 2024 Jun;
30(8):2372.
PMID: 38890533
No abstract available.
7.
Li R, Shah P, Stewart T, Nam J, Bivalacqua T, Lamm D, et al.
Nat Med
. 2024 Jun;
30(8):2216-2223.
PMID: 38844794
Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette-Guérin (BCG)-experienced non-muscle-invasive bladder cancer. In...
8.
Patel S, Gabrielson A, Chan S, Schwartz D, Collins C, Singla N, et al.
J Urol
. 2024 May;
212(1):103.
PMID: 38713596
No abstract available.
9.
Narayan V, Boorjian S, Alemozaffar M, Konety B, Shore N, Gomella L, et al.
J Urol
. 2024 May;
212(1):74-86.
PMID: 38704840
Purpose: Nadofaragene firadenovec-vncg is a nonreplicating adenoviral vector-based gene therapy for bacillus Calmette-Guérin (BCG)-unresponsive carcinoma in situ (CIS) with/without high-grade Ta/T1. We report outcomes following 5 years of planned follow-up....
10.
Xia L, Dadabhoy A, Wood E, Mehta S, Roberson D, Guzzo T, et al.
Urol Oncol
. 2024 May;
42(10):333.e1-333.e13.
PMID: 38697874
Objective: To compare survival and pathologic outcomes in patients with progressive muscle-invasive bladder cancer (pgMIBC) and de novo muscle-invasive bladder cancer (dnMIBC) after radical cystectomy (RC), with a focus on...